COVID Exposure Treatment: What to Know About XOCOVA
COVID-19 may no longer dominate daily life the way it once did, but that does not mean it has disappeared. People are still getting infected, households are still passing the virus around and for some, even a “mild” case can lead to weeks or months of lingering symptoms.
That matters deeply for midlife women, who remain disproportionately vulnerable to long COVID. Research has consistently shown that women are more likely than men to develop the condition, with some data suggesting risk may be especially elevated in women ages 40 to 54. And while scientists are still working to understand why, immune differences, hormones, autoimmune risk and social factors may all play a role.
Now, there is a preemptive treatment to prevent infection after a known exposure, before symptoms begin.
The Food and Drug Administration (FDA) has approved XOCOVA, also known as ensitrelvir, for adults and adolescents ages 12 and older after contact with someone who has tested positive for COVID-19. According to Shionogi, the company behind the drug, XOCOVA is expected to be available by prescription in July 2026.
“XOCOVA is an oral antiviral,” Dr. Paul Sax, clinical director of the Division of Infectious Diseases at Brigham and Women’s Hospital, tells Flow Space. “The idea is to start it early, during the window when the virus may be starting to replicate but before symptoms have begun, lowering the risk that an exposed person will go on to develop symptomatic COVID-19.”
The FDA approval is based on SCORPIO-PEP, a global, double-blind, randomized Phase 3 study of people who had been exposed to COVID-19 at home. In the trial, a five-day course of XOCOVA reduced the risk of symptoms after known contact by 67% compared with a placebo, according to results published last month in The New England Journal of Medicine.
That does not mean this is a pill to take after every crowded subway ride, summer wedding or suspicious cough nearby.
“The most obvious setting is a household exposure, because that is where people often have prolonged, close contact with someone who is infected,” notes Sax. “It’s also the setting that the SCORPIO-PEP trial studied.”
He says the option may be especially relevant when the exposed person is at higher risk for complications or when someone is trying to protect a vulnerable household member. That could include older adults, immunocompromised people, caregivers and families living in multigenerational households.
For many midlife women, that last point may feel familiar. This is an age when women are often caring in multiple directions at once — for children, partners, parents, in-laws and themselves. An infection is not just an inconvenience when it can derail caregiving, worsen an underlying condition or potentially trigger long COVID.
“COVID-19 is not the emergency it was in 2020, but it has not disappeared,” Sax says. “People are still getting infected, and some still become seriously ill — especially older adults and people with underlying medical conditions.”
Timing is also critical. In the SCORPIO-PEP trial, participants started treatment within 72 hours of the household member with the virus developing symptoms. Sax says the practical message is not to wait and see whether symptoms appear.
“If you have had a close exposure to someone with COVID-19, contact a healthcare professional promptly to ask whether XOCOVA is appropriate for you,” he says.
The drug will be available by prescription only.
The list price is $1,400 for a course of treatment, though Margaret Borys, executive vice president and chief commercial officer of Shionogi Inc., says patient costs will vary by insurance coverage. Eligible commercially insured patients may be able to access XOCOVA through a $0 copay assistance program, but that offer is not available to uninsured patients, cash-paying patients or people with government insurance, including Medicare, Medicaid, TRICARE or VA health benefit programs.
XOCOVA was generally well tolerated in the trial, with similar rates of adverse events in the treatment and placebo groups. The most common side effects included headache, diarrhea and cough.
While this drug does not replace vaccines, testing, masking or common-sense precautions during surges, it offers another option for people with a clear exposure, especially in a household or caregiving setting. And for midlife women, that prevention window matters. Because the best way to reduce the risk of long COVID is still to avoid getting COVID in the first place.
Comments (0)